LYFE Capital is a life science investment firm.
Business Model:
Revenue: $0
Employees: 0-0
Address: Suite 1804, UNITED PLAZA
City: Shanghai
State: shanghai municipality
Zip: 200040
Country: CN
In our inaugural fund, we are only seeking biotechnology, pharmaceutical, medical device, diagnostic, healthcare service and digital health companies with an established product foundation but need a bit more capital to accelerate its growth in Greater China. During this critical time, we work closely with our portfolio companies and support their needs not only by providing capital but with market planning, talent acquisition, global expansion and global partnership support.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2015 | Zhangkong Tangniaobing | Series A | 9.7M |
3/2021 | ImmuneOnco Biopharma | Series C | - |
12/2016 | Burning Rock Biotech | Series B | 43.1M |
4/2022 | Elixir Clinical Research | Series A | 0 |
12/2022 | Dieshi-DISC | Series A | 12.9M |
9/2018 | Aohua | Series D | 43.7M |
7/2021 | ProfoundBio | Series A | 0 |
8/2020 | Shenqi Medical | Series C | 14.5M |
2/2021 | ABclonal | Series C | 0 |
1/2018 | Laviana Pharma | Series B | 15M |
3/2020 | Zhenge Biotech | Series A | 51M |
4/2022 | Levostar | Seed Round | - |
10/2020 | ImmuneOnco Biopharma | Series B | 25M |
7/2022 | MobiDrop | Series A | 13.3M |
1/2021 | Edge Medical Robotics | Series B | 92.8M |
5/2021 | Jianjia Robot | Series C | - |
5/2018 | HiFiBiO | Series B | 37.5M |
10/2022 | Edgene Biot | Angel Round | - |
1/2023 | Genepoint Biological Technology | Series D | 29.5M |
4/2021 | Molecular Assemblies | Series A | 0 |
5/2021 | Zhenyi Yiliao | Series A | - |
6/2021 | RecBio | Series C | 156.3M |
11/2022 | iECURE | Series A | 0 |
6/2022 | ProfoundBio | Series A | 0 |
4/2021 | Nucleix | Venture Round | 55M |
9/2014 | WinnTi Medical | Series A | 13M |
11/2017 | Baixing Pingan Yaofang | Venture Round | 30.3M |
3/2022 | Medilink Therapeutics | Series B | 70M |
8/2015 | Burning Rock Biotech | Series A | 23.5M |
2/2021 | Cleveland Diagnostics | Series D | 17.4M |
4/2021 | Abogen Biosciences | Series B | 91.6M |
1/2022 | Zhenge Biotech | Series C | 100M |
7/2021 | neoX Biotech | Venture Round | - |
5/2022 | Starna Therapeutics | Series A | 0 |
2/2021 | Exegenesis Bio | Series B | - |
2/2019 | Burning Rock Biotech | Series C | 125.5M |
3/2022 | Molecular Assemblies | Series B | 0 |
2/2022 | Genepoint Biological Technology | Series C | 0 |
10/2021 | Sciwind Biosciences | Series C | 0 |
11/2020 | Cytek Biosciences | Series D | 120M |
12/2020 | CANbridge Pharmaceuticals | Series E | 0 |
11/2020 | RecBio | Series B | 0 |
4/2022 | Shenji Bio | Series A | 47.1M |
5/2022 | Boyue Bio | Series A | 22.3M |
8/2019 | Just Medical | Series A | - |
9/2021 | HC Scientific | Series B | 31M |
5/2018 | Ansun BioPharma | Series A | 85M |
8/2019 | HiFiBiO | Series C | 0 |
2/2021 | Sciwind Biosciences | Series B | 37M |
11/2021 | Edge Medical Robotics | Series C | 0 |
5/2022 | Aspen Neuroscience | Series B | 0 |
1/2022 | Kyverna Therapeutics | Series B | 0 |
7/2022 | MobiDrop | Series A | 0 |
6/2022 | ProfoundBio | Series A | 0 |
5/2022 | Starna Therapeutics | Series A | 0 |
5/2022 | Aspen Neuroscience | Series B | 0 |
5/2022 | Boyue Bio | Series A | 0 |
4/2022 | Elixir Clinical Research | Series A | 0 |
4/2022 | Shenji Bio | Series A | 0 |
3/2022 | Molecular Assemblies | Series B | 0 |
3/2022 | Medilink Therapeutics | Series B | 0 |
2/2022 | Genepoint Biological Technology | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|